Vaccination Status Not Associated With Acute Thromboembolism Risk in COVID-19
A total of 1428 patients were included in the analysis, of whom 185 (13%) were vaccinated and 1243 (87%) were unvaccinated against COVID-19 infection.
COVID19
COVID-19 Increases Risk for Gastrointestinal and Autonomic Dysfunction
After COVID-19, the risk for GI diagnoses and AN was increased, compared with the other control populations, except for patients with GI diagnoses after CMV.
Flu, COVID-19 Vaccination Cover High Among Health Care Personnel
HCP who reported employer vaccination requirements had higher vaccination coverage for flu, COVID-19 primary series, COVID-19 booster
Antibiotic Overuse Common in Children Hospitalized With COVID-19
Bacterial culture growth was reported in 13 (14%) patients, and 5 (5%) had urinary tract or bloodstream infections.
Individuals With HIV and Cognitive Impairment at Increased Risk for COVID-19 Mortality
Research has shown that PLWH are at increased risk for cognitive disorders, including dementia. In addition, dementia is known to be a risk factor for COVID-19 mortality.
CDC Panel: Add COVID-19 Shot to Routine Vaccine Schedule
The next step is for the CDC to decide whether to follow the advice of the Advisory Committee on Immunization Practices
High-Dose Dexamethasone May Be Harmful for Patients With COVID-19
Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.
Severe COVID-19 Is Associated With Post-Discharge ILD in Patients Without Cancer
Should patients without cancer who have recovered from severe COVID-19 infection be referred to post-COVID clinics based on their risk for interstitial lung disease?
NIH Investigating COVID-19 Experiments Conducted at Boston University
Boston University is refuting the news accounts, calling them a “false and inaccurate” interpretation of its research.
FDA Authorizes Booster Dose of Novavax COVID-19 Vaccine, Adjuvanted
Findings showed that the booster dose elicited robust antibody responses comparable to, or exceeding levels associated with the efficacy data in the primary series of the vaccine.
